Iopanoic acid |
| Catalog No.GC32404 |
L'acide iopanoÏque est un inhibiteur de la 5'-Deiodinase et également un produit de contraste iodé.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 96-83-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Iopanoic acid is an inhibitor of 5'-Deiodinase and also an iodinated contrast medium.
The thyrotropin-releasing-hormone (TRH)-induced thyrotropin (TSH) release from the pituitary fragments is inhibited by 3,5,3'-triiodothyronin (T3) (10-7 M), by triiodothyroacetic acid (10-7 to 10-7 M), and by high concentrations of iodide (10-4 or 10-5 M). Iopanoic acid has no significant effect at the concentrations tested[2].
Iopanoic acid (IOP) administration to pregnant rats during days 18 and 19 postconception does not modify litter size (controls: 11.8±0.5 fetusesldam, Iopanoic acid-treated: 11.6±0.6 fetusesldam) or body weight at day 20 (controls: 3.27±0.12 g, Iopanoic acid-treated: 3.42±0.20 g). Iopanoic acid treatment produces a significant blockage of 5'-Deiodinase (5'D) activity in interscapular brown adipose tissue (IBAT) and brain; in contrast, liver 5'D is not modified. 3,5,3'-triiodothyronin (T3) content is similar in IBAT and slightly increased in brain and liver nuclei of Iopanoic acid-treated fetuses when compare with control fetuses at day 20 (p<0.05). However, when administered to adult rats, Iopanoic acid produces a significant reduction in IBAT nuclear T3 content and plasma T3 concentration. Iopanoic acid inhibition of IBAT 5'D activity in fetuses at term is as effective as at day 20[1].
[1]. Tuca A, et al. Inhibition of iodothyronine 5'-deiodinase by iopanoic acid does not block nuclear T3 accumulation during rat fetal development. Pediatr Res. 1994 Jan;35(1):91-5. [2]. Szabolcs I, et al. Effects of triiodothyronine, triiodothyroacetic acid, iopanoic acid and iodide on the thyrotropin-releasing hormone-induced thyrotropin release from superfused rat pituitary fragments. Acta Endocrinol (Copenh). 1991 Oct;125(4):427-34.
Cell experiment: | Rat pituitary fragments are superfused by Medium-199. After a 90 min equilibration period, the superfusion is continued for 135 min with or without inclusion into the superfusion medium of 3,5,3'-triiodothyronin (T3) 10-7 M, triiodothyroacetic acid (TRIAC) (stock solution 10-4 M in 20% methanol, final concentrations 10-8 to 10-6 M), Iopanoic acid (stock solution 10-3 M in 0.2 M NaOH, final concentrations 10-7 to 10-5 M), or potassium iodide 10-7 to 10-4 M. The superfusion is followed by a 6-min pulse of thyrotropin-releasing-hormone (TRH)[2]. |
Animal experiment: | Wistar rats initially weighing 180 to 200 g are used. The administration of Iopanoic acid (IOP) is started at day 18 of gestation. Pregnant rats are injected subcutaneously with 10 mg of Iopanoic acid every 12 h, from day 18 of gestation to 12 h before they are killed on the morning of day 20 or 22 of gestation. Control animals receive the vehicle solution with identical timing. Iopanoic acid effectiveness in decreasing interscapular brown adipose tissue (IBAT) nuclear 3,5,3'-triiodothyronin (T3) is assessed by Iopanoic acid (IOP) administration to adult male rats (220 to 250 g body weight) following the same dose and time schedule as in pregnant dams during two days. Caesarean sections are performed at 18 (only untreated animals), 20 and 22 days of gestation. Fetuses are killed by decapitation, and IBAT, brain, and liver are removed. Tissue samples are immediately frozen in liquid nitrogen with the exception of brown fat from several 22 day-old fetuses, which is directly homogenized in 0.25 M sucrose for mitochondria isolation[1]. |
References: [1]. Tuca A, et al. Inhibition of iodothyronine 5'-deiodinase by iopanoic acid does not block nuclear T3 accumulation during rat fetal development. Pediatr Res. 1994 Jan;35(1):91-5. | |
| Cas No. | 96-83-3 | SDF | |
| Canonical SMILES | O=C(O)C(CC)CC1=C(I)C=C(I)C(N)=C1I | ||
| Formula | C11H12I3NO2 | M.Wt | 570.93 |
| Solubility | DMSO : 113.3 mg/mL (198.45 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7515 mL | 8.7576 mL | 17.5153 mL |
| 5 mM | 350.3 μL | 1.7515 mL | 3.5031 mL |
| 10 mM | 175.2 μL | 875.8 μL | 1.7515 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *